133 related articles for article (PubMed ID: 38701193)
1. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M; Friedrich MJ; Lu KH; Vonhören D; Jansky S; Michel J; Keib A; Stange S; Hackert N; Kehl N; Hahn M; Habel A; Jung S; Jähne K; Sahm F; Betge J; Cerwenka A; Westermann F; Dreger P; Raab MS; Meindl-Beinker NM; Ebert M; Bunse L; Müller-Tidow C; Schmitt M; Platten M
Sci Immunol; 2024 May; 9(95):eadj7970. PubMed ID: 38701193
[TBL] [Abstract][Full Text] [Related]
2. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.
Hua CK; Gacerez AT; Sentman CL; Ackerman ME
Protein Eng Des Sel; 2017 Oct; 30(10):713-721. PubMed ID: 29040754
[TBL] [Abstract][Full Text] [Related]
3. B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines.
Bjørnsen EG; Thiruchelvam-Kyle L; Hoelsbrekken SE; Henden C; Saether PC; Boysen P; Daws MR; Dissen E
Eur J Immunol; 2019 Jan; 49(1):54-65. PubMed ID: 30512185
[TBL] [Abstract][Full Text] [Related]
4. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
Phillips M; Romeo F; Bitsaktsis C; Sabatino D
Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
[TBL] [Abstract][Full Text] [Related]
5. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.
Wu MR; Zhang T; DeMars LR; Sentman CL
Gene Ther; 2015 Aug; 22(8):675-84. PubMed ID: 25830550
[TBL] [Abstract][Full Text] [Related]
6. Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy.
Gutierrez-Franco J; Hernandez-Gutierrez R; Bueno-Topete MR; Haramati J; Navarro-Hernandez RE; Escarra-Senmarti M; Vega-Magaña N; Del Toro-Arreola A; Pereira-Suarez AL; Del Toro-Arreola S
Immunobiology; 2018 Jan; 223(1):57-63. PubMed ID: 29055565
[TBL] [Abstract][Full Text] [Related]
7. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.
Butler SE; Brog RA; Chang CH; Sentman CL; Huang YH; Ackerman ME
Cancer Immunol Immunother; 2022 Jan; 71(1):165-176. PubMed ID: 34046711
[TBL] [Abstract][Full Text] [Related]
8. The integrated stress response promotes B7H6 expression.
Obiedat A; Charpak-Amikam Y; Tai-Schmiedel J; Seidel E; Mahameed M; Avril T; Stern-Ginossar N; Springuel L; Bolsée J; Gilham DE; Dipta P; Shmuel M; Chevet E; Mandelboim O; Tirosh B
J Mol Med (Berl); 2020 Jan; 98(1):135-148. PubMed ID: 31838577
[TBL] [Abstract][Full Text] [Related]
9. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.
Wu MR; Zhang T; Gacerez AT; Coupet TA; DeMars LR; Sentman CL
J Immunol; 2015 Jun; 194(11):5305-11. PubMed ID: 25911747
[TBL] [Abstract][Full Text] [Related]
10. Coevolution of MHC genes (LMP/TAP/class Ia, NKT-class Ib, NKp30-B7H6): lessons from cold-blooded vertebrates.
Ohta Y; Flajnik MF
Immunol Rev; 2015 Sep; 267(1):6-15. PubMed ID: 26284468
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.
Gacerez AT; Hua CK; Ackerman ME; Sentman CL
Cancer Immunol Immunother; 2018 May; 67(5):749-759. PubMed ID: 29453518
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.
Flajnik MF; Tlapakova T; Criscitiello MF; Krylov V; Ohta Y
Immunogenetics; 2012 Aug; 64(8):571-90. PubMed ID: 22488247
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
14. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
[TBL] [Abstract][Full Text] [Related]
15. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
16. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
17. Non-fitness status of peripheral NK cells defined by decreased NKp30 and perforin, and increased soluble B7H6, in cervical cancer patients.
Gutierrez-Silerio GY; Bueno-Topete MR; Vega-Magaña AN; Bastidas-Ramirez BE; Gutierrez-Franco J; Escarra-Senmarti M; Pedraza-Brindis EJ; Peña-Rodriguez M; Ramos-Marquez ME; Delgado-Rizo V; Banu N; Alejandre-Gonzalez AG; Fafutis-Morris M; Haramati J; Del Toro-Arreola S
Immunology; 2023 Mar; 168(3):538-553. PubMed ID: 36271832
[TBL] [Abstract][Full Text] [Related]
18. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
19. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
Zhuang X; Long EO
Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
